Urothelial Cancer

Somatic Genomic Alterations in Urothelial Cancer

Details
Somatic Genomic Alterations in Urothelial Cancer: Results of the Cancer Genome Atlas (TCGA) Bladder Cancer Analysis Jonathan E. Rosenberg, MD Click HERE to read an exclusive report by a UroToday medical writer Click HERE to view the poster from this session

NeuACT, a Phase II trial of DN24-02 in Patients with Surgically Resected HER2+ Urothelial Cancer

Details
Summary of SUO 2013 poster, "NeuACT, a Phase 2 Randomized, Open-label Trial of DN24-02 in Patients with Surgically Resected HER2+ Urothelial Cancer: Updated Analysis of Product Parameters, HER2 Expression and Safety" Leonard G. Gomella, MD, FACS Thomas Jefferson University Hospital Click HERE to read the abstract and view the poster Click HERE to read a report from this session by the Fox Chase Ca...

mTOR Pathway Biomarkers in Upper Tract Urothelial Carcinoma

Details
SUO 2013 - Evaluation of the Prognostic Significance of Altered Mammalian Target of Rapamycin (MTOR) Pathway Biomarkers in Upper Tract Urothelial Carcinoma Click HERE to read session highlights from the meeting, reported by the Fox Chase Cancer Center team.
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe